These novel medications , Tirzepatide , represent a groundbreaking advancement in managing obesity and possibly related disorders. They are categorized as GLP-1 hormone agonists , signifying they https://luluxzjg330923.yomoblog.com/48768856/semaglutide-a-thorough-dive-into-incretin-agents